AGIO — Agios Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $1.63bn
- $777.95m
- $54.03m
Annual income statement for Agios Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 14.2 | 26.8 | 36.5 | 54 |
| Cost of Revenue | |||||
| Gross Profit | — | 12.5 | 23.9 | 32.3 | 47.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 372 | 266 | 418 | -627 | 526 |
| Operating Profit | -372 | -251 | -391 | 663 | -472 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -357 | -232 | -352 | 718 | -414 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -357 | -232 | -352 | 674 | -413 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 1,605 | -232 | -352 | 674 | -413 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1,605 | -232 | -352 | 674 | -413 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.01 | -6.74 | -6.33 | -0.591 | -7.12 |